Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
None
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC).

cyclophosphamide
lymphocytosis
chronic lymphocytic leukemia
chlorambucil
thrombocytopenia
  • 436 views
  • 08 Nov, 2020
  • 1 location
None
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma

approved for clinical use. It is an anti CD20 antibody with high response rate in the treatment of follicular lymphoma and increases response rate in aggressive lymphoma when combined with

cell transplantation
transplant conditioning
zevalin
monoclonal antibodies
lymphoma cell count
  • 26 views
  • 07 Nov, 2020
  • 1 location
None
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

The aim of this study is to determine whether alternating courses of cyclophosphamide, doxorubicin, vincristine, prednisone/dexamethasone, cytarabine, cisplatin (CHOP/DHAP) plus rituximab followed by total body irradiation [TBI]/high dose cytarabine [ARA-C]/melphalan-peripheral blood stem cell transplantation (TAM-PBSCT) can improve the time to treatment failure compared to CHOP plus rituximab followed by standard …

dexamethasone
granulocyte colony stimulating factor
melphalan
cyclophosphamide
measurable disease
  • 160 views
  • 07 Nov, 2020
  • 2 locations
None
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

including an anti-CD20 antibody and an alkylating agent 3 according to Lugano Classification and as assessed by independent central review and local investigator evaluation

refractory b-cell non-hodgkin lymphoma
measurable disease
alkylating agent
renal function
diffuse large b-cell lymphoma
  • 52 views
  • 10 Dec, 2021
  • 91 locations
None
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

refractory follicular lymphoma
follicular lymphoma
marginal zone lymphoma
ejection fraction
ct scan
  • 194 views
  • 17 Jan, 2022
  • 143 locations
None
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged 18 to 80 will be included in this study. The treatment regimen is a single dose anti-CD20 antibody

prednisone
treatment regimen
  • 2 views
  • 21 Oct, 2021
  • 1 location
None
Obinutuzumab in Marginal Zone Lymphoma

. The type II anti-CD20 antibody Obinutuzumab (OBINUTUZUMAB) has demonstrated remarkable activity in follicular lymphoma and superiority to Rituximab in combination with chemotherapy in treatment nave

gastric malt lymphoma
interferon
chlorambucil
remission
refractory follicular lymphoma
  • 25 views
  • 02 Feb, 2021
  • 24 locations
None
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment. Monoclonal anti-CD20 antibody, rituximab, in

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and

immunoglobulin g
anti-cd20 antibody
immunosuppressants
enzyme-linked immunosorbent assay
intravenous immunoglobulin
  • 77 views
  • 02 Jun, 2021
  • 1 location
None
Ibrutinib Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL IPI 2

-phase therapy with Prednisone and 6 cycles of a combined immuno-chemotherapy with the anti-CD20 antibody Rituximab together with 6 cycles of a chemotherapy consisting of Cyclophosphamide, Doxorubicin

cyclophosphamide
renal function
ibrutinib
tositumomab
rituximab
  • 4 views
  • 28 Jan, 2021
  • 2 locations